We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$356M
AUM Growth
+$69.2M
Cap. Flow
+$89M
Cap. Flow %
25.02%
Top 10 Hldgs %
43.39%
Holding
101
New
33
Increased
27
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$23M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.27M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$8.98M
4
KRYS icon
Krystal Biotech
KRYS
+$7.02M
5
ACLX
Arcellx
ACLX
+$5.99M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.3M
2
BIIB icon
Biogen
BIIB
+$11.4M
3
VTYX
Ventyx Biosciences
VTYX
+$3.3M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.97M
5
KYNB
Kyntra Bio
KYNB
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 81.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$4.35M 1.22%
+1,150,000
New +$4.1M
ASND icon
27
Ascendis Pharma A/S
ASND
$16.5B
$4.34M 1.22%
46,400
-11,360
-20% -$1.06M
CLDX icon
28
Celldex Therapeutics
CLDX
$2.78B
$4.13M 1.16%
150,000
+62,969
+72% +$1.97M
AZN icon
29
AstraZeneca
AZN
$255B
$4.06M 1.14%
30,000
– –
TNGX icon
30
Tango Therapeutics
TNGX
$4.48B
$3.94M 1.11%
+350,000
New +$2.13M
PRTA icon
31
Prothena Corp
PRTA
$454M
$3.82M 1.08%
79,214
-20,786
-21% -$1.23M
VKTX icon
32
PUT
Viking Therapeutics
VKTX
$4.22B
$3.68M 1.04%
332,600
-17,400
-5% -$249K
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
$3.62M 1.02%
+114,000
New +$5.42M
VKTX icon
34
Viking Therapeutics
VKTX
$4.22B
$3.32M 0.93%
300,000
– –
SYRE icon
35
Spyre Therapeutics
SYRE
$8.45B
$2.97M 0.83%
242,297
+46,297
+24% +$612K
DVAX
36
DELISTED
Dynavax Technologies
DVAX
$2.95M 0.83%
+200,000
New +$2.81M
MLTX icon
37
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.85M 0.8%
+50,000
New +$2.76M
ALKS icon
38
Alkermes
ALKS
$8.62B
$2.8M 0.79%
+100,000
New +$2.93M
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
$2.68M 0.75%
278,292
+100,000
+56% +$1.02M
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.63M 0.74%
+60,426
New +$2.16M
IMTX icon
41
Immatics
IMTX
$1.26B
$2.32M 0.65%
200,000
-100,000
-33% -$1.19M
NUVL
42
DELISTED
Nuvalent
NUVL
$2.3M 0.65%
+50,000
New +$2.22M
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
$2.12M 0.6%
+10,000
New +$2M
LNTH icon
44
Lantheus
LNTH
$6.8B
$2.08M 0.59%
+30,000
New +$2.19M
NRIX icon
45
Nurix Therapeutics
NRIX
$2.36B
$1.97M 0.55%
250,000
+150,000
+150% +$1.37M
ACRS icon
46
PUT
Aclaris Therapeutics
ACRS
$778M
$1.78M 0.5%
+260,000
New +$2.22M
ROIV icon
47
Roivant Sciences
ROIV
$24.5B
$1.75M 0.49%
+150,000
New +$1.7M
TERN
48
DELISTED
Terns Pharmaceuticals
TERN
$1.63M 0.46%
+325,000
New +$2.06M
APLS
49
DELISTED
Apellis Pharmaceuticals
APLS
$1.52M 0.43%
40,000
+30,000
+300% +$1.32M
PCVX icon
50
Vaxcyte
PCVX
$8.01B
$1.27M 0.36%
25,000
+11,077
+80% +$546K
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Affinity Asset Advisors held 101 positions worth $356M, up 24% from $286M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $89M of net new capital in Q3 2023, opening 33 new positions and adding to 27 existing holdings. Its largest new stake was Apogee Therapeutics: 1,045,110 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $2.42M trimmed.

  • Affinity Asset Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,045,110 shares worth $22.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q3 2023, an estimated $8.98M increase.
  • Affinity Asset Advisors's biggest Q3 2023 reduction was SpringWorks Therapeutics, cutting an estimated $2.42M.
  • Affinity Asset Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $12.3M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $356M portfolio in Q3 2023.
  • Affinity Asset Advisors opened 33 new positions and closed 20 in Q3 2023.
  • Affinity Asset Advisors's portfolio value rose 24% quarter-over-quarter to $356M.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.